X0306 4 2018-11-02 1 0001603756 Axonics Modulation Technologies, Inc. AXNX 0001601364 Advent Life Sciences LLP 158 NORTH GOWER STREET LONDON X0 NW1 2nd UNITED KINGDOM 0 0 0 1 Former 10% Owner 0001614918 Advent Life Sciences Fund II LP 158 NORTH GOWER STREET LONDON X0 NW1 2nd UNITED KINGDOM 0 0 0 1 Former 10% Owner Common Stock 2018-11-02 4 C 0 43822 A 43822 I By Advent Life Sciences LLP Common Stock 2018-11-02 4 C 0 1231178 A 1275000 I By Advent Life Sciences Fund II LP Common Stock 2018-11-02 4 C 0 14412 A 1289412 I By Advent Life Sciences LLP Common Stock 2018-11-02 4 C 0 404937 A 1694349 I By Advent Life Sciences Fund II LP Series B-2 Preferred Stock 2018-11-02 4 C 0 36518 0.00 D Common Stock 43822 0 I By Advent Life Sciences LLP Series B-2 Preferred Stock 2018-11-02 4 C 0 1025981 0.00 D Common Stock 1231178 0 I By Advent Life Sciences Fund II LP Series C Preferred Stock 2018-11-02 4 C 0 12010 0.00 D Common Stock 14412 0 I By Advent Life Sciences LLP Series C Preferred Stock 2018-11-02 4 C 0 337447 0.00 D Common Stock 404937 0 I By Advent Life Sciences Fund II LP Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018. Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series B-2 preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The B-2 preferred stock had no expiration date. Securities are held by Advent Life Sciences LLP. Securities are held by Advent Life Sciences Fund II LP. Advent Life Sciences LLP is the general partner of Advent Life Sciences Fund II LP. Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series C preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The C preferred stock had no expiration date. /s/ Shahzad Malik, General Partner, Advent Life Sciences LLP 2018-11-02 /s/ Shahzad Malik, General Partner of Advent Life Sciences LLP, acting in its capacity as Manager of Advent Life Sciences Fund II LP 2018-11-02